PMID- 37217393
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20230801
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 17
IP  - 4
DP  - 2023 Aug
TI  - Relationship between the insulin use and stigma in type 2 diabetes mellitus.
PG  - 373-378
LID - S1751-9918(23)00097-9 [pii]
LID - 10.1016/j.pcd.2023.05.002 [doi]
AB  - AIMS: This study aimed to investigate the relationship between insulin use and 
      stigma in Type 2 Diabetes Mellitus (T2DM). METHODS: The study was carried out in 
      the endocrinology and metabolic disorders outpatient clinic of a state hospital 
      between February and October 2022. The study was carried out with 154 patients, 
      77 of them were treated with insulin while 77 were treated with peroral 
      antidiabetic drugs (PAD). The patient identification form and Type 2 Diabetes 
      Stigma Assessment Scale (DSAS-2) were used for data collection. The data were 
      analyzed by using IBM SPSS 26.0 software. RESULTS: DSAS-2 total score, treated 
      differently, blame and judgment, and self-stigma subscales were higher in 
      insulin-treated T2DM patients compared to the patients treated with PAD. There 
      was a positive relationship between the number of daily injections and the DSAS-2 
      total score (r = 0.554). Multiple linear regression showed that type of the 
      treatment, treatment duration, number of daily injections and perceived level of 
      health were the determinants of the DSAS-2 score. CONCLUSIONS: Stigma was high in 
      insulin-treated T2DM patients and as the number of daily injections increased, 
      the level of the perceived stigma increased. We recommend considering the high 
      level of perceived stigma in insulin-treated T2DM patients while preparing 
      nursing investigations.
CI  - Copyright (c) 2023 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Aslan, Emine Ozdemir
AU  - Aslan EO
AD  - Bahcesehir University, Faculty of Health Sciences, Department of Nursing, 
      Istanbul, Turkey.
FAU - Toygar, Ismail
AU  - Toygar I
AD  - Mugla Sitki Kocman University, Fethiye Faculty of Health Sciences, Mugla, Turkey. 
      Electronic address: ismail.toygar1@gmail.com.
FAU - Feyizoglu, Gunes
AU  - Feyizoglu G
AD  - Diabetes-specialist Nurse, Istanbul Goztepe Prof. Dr. Suleyman Yalcin City 
      Hospital, Endocrinology and Metabolic Disorders Department, Istanbul, Turkey.
FAU - Polat, Selda
AU  - Polat S
AD  - Bahcesehir University, Faculty of Health Sciences, Department of Nursing, 
      Istanbul, Turkey.
FAU - Eti Aslan, Fatma
AU  - Eti Aslan F
AD  - Bahcesehir University, Faculty of Health Sciences, Department of Nursing, 
      Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230521
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Hypoglycemic Agents/adverse effects
MH  - Insulin/adverse effects
MH  - Multivariate Analysis
MH  - Social Stigma
OTO - NOTNLM
OT  - Insulin
OT  - Nursing
OT  - Stigma
OT  - Type 2 diabetes mellitus
COIS- Declaration of Competing Interest None.
EDAT- 2023/05/23 01:06
MHDA- 2023/08/01 06:44
CRDT- 2023/05/22 21:58
PHST- 2023/01/06 00:00 [received]
PHST- 2023/04/13 00:00 [revised]
PHST- 2023/05/11 00:00 [accepted]
PHST- 2023/08/01 06:44 [medline]
PHST- 2023/05/23 01:06 [pubmed]
PHST- 2023/05/22 21:58 [entrez]
AID - S1751-9918(23)00097-9 [pii]
AID - 10.1016/j.pcd.2023.05.002 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2023 Aug;17(4):373-378. doi: 10.1016/j.pcd.2023.05.002. Epub 
      2023 May 21.